The in vitro effects of crystalloids and colloids on coagulation.

Worth a close look for those with a specialist interest in this area. Adds to a fast growing body of literature on the various effects of i.v. solutions on coagulation in-vitro. We wait with baited breath for the clinical studies. – Monty Mythen There are two major disturbing points about this article. Firstly, the main […]

Treatment of critical bleeding in the future intensive care unit. [Editorial]

Uncontrolled bleeding remains a major problem in intensive care and emergency medicine which still requires effective and innovative treatment options. This editorial highlights that there is growing evidence on the efficacy of rFVIIa (Novoseven) in controlling such bleeding, and that clinical trials in different patient populations are required to assess its efficacy and safety. – […]

Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: A pilot study.

This is an interesting work showing the efficacy of rFVIIa in controlling post traumatic hemorrhage in an animal model, especially after the publication of several case reports of the effective treatment of excessive bleeding following surgery or trauma in non-hemophiliac patients with rFVIIa. After avulsion of left median lobe of the liver, swines were randomized […]

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Etiology of bleeding in cirrhotic patients during surgery is multifactorial, and its management includes several measures such as replacement of coagulation factors and platelets as well as the use of antifibrinolytic agents. Recombinant factor VIIa has been shown to normalize prothrombin time in patients with liver disease and to reduce transfusion requirement during OLT. In […]

Use of recombinant factor VII in hepatology.

This article starts with a general overview on mechanism of action, uses and safety of rFVIIa as well as the hemostatic disorders which are associated with liver disease. It states the correlation between the degree of liver damage and level and gene expression of FVII. The authors reviewed the use of rFVIIa in liver disease […]

Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.

This is a double-blind placebo controlled dose escalation trial evaluating efficacy and safety of inactivated rFVIIa (FFR-rFVIIa) as an antithrombotic agent. The trial showed a dose dependent prolongation of the prothrombin time. Future studies in patients undergoing vascular intervention are required. – M. Aldouri. FFR-rFVIIa is a variant activated factor VII molecule that is characterised […]